Table 1.

Summary of retrospective studies of therapeutic effect and overall survival of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma

Ref.	Year	No. of patients	Antitumor agent and embolic materials	Therapeutic effect	Overall survival	Commentary
Hatanaka et al[43]	2018	66	Miriplatin-lipiodol suspension + gelatin particle	CR 53.0%, PR 10.6%, SD 19.7%, PD 16.7%, RR 63.6%	The 1-, 2-, and 3-yr survival rates were 76.8%, 57.3%, and 46.7%, respectively	The number of tumors and α-fetoprotein level were predictive factors for the tumor response and serum albumin and overall response (CR + PR) were predictive factors for prognosis
Kawamura et al[40]	2017	30	Miriplatin-lipiodol suspension + gelatin particle	TE4 51.0%, TE3 8.5%, TE2 19.1%, TE1 21.3%, RR 59.6%	NA	The presence of portal vein visualization, tumor on the subcapsular portion, and successful subsegmental artery embolization were predictive factors for the tumor response
Maruyama et al[20]	2016	50	Epirubicin-lipiodol suspension + gelatin particle	There was no statistically significant difference between the B-TACE group and the C-TACE group	NA
Irie et al[15]	2016	28	Doxorubicin, mytomysin-lipiodol suspension + gelatin particle	TE4 89.3%, TE3 10.7%, TE2 0%, TE1 0%, RR 100%. The local recurrence rates at 1, 3, and 5 yr were 92.4%, 69.9%, and 69.9%, respectively	The 1-, 3-, and 5-yr survival rates were 96.4%, 60.3% and 31.1%, respectively	B-TACE was an independent factor for improving both the control rate of the primary nodule and the overall survival rates
Asayama et al[32]	2016	29	Miriplatin-lipiodol suspension + gelatin particle	TE4 8.6%, TE3 48.6%, TE2 17.1%, TE1 25.7%, RR 57.1%	NA
Ogawa et al[14]	2015	33	Miriplatin-lipiodol suspension + gelatin particle	TE4 49.2%	NA	The percentage of TE4 in B-TACE was significantly higher than that in the C-TACE
Minami et al[41]	2015	27	Miriplatin-lipiodol suspension + gelatin particle (epirubicin was used in 3 patients)	Countable HCC (n = 17): TE4 43.8%, TE3 12.5%, TE2 37.5%, TE1 6.3%, RR 56.3%, Uncountable HCC (n = 10): CR 0%, PR 0%, SD 10%, PD 90%	NA
Arai et al[13]	2014	49	Miriplatin-lipiodol suspension + gelatin particle	TE4 55.1%, TE3 38.8%, TE2 4.1%, TE1 2.0%, RR 93.9%	NA
Ishikawa et al[44]	2014	51	Miriplatin-lipiodol suspension + gelatin particle	The local recurrence rates at 6, 12 mo were 11.1 %, 26.2%, respectively. The medan recurrence time was 9 mo	NA	The CT value just after B-TACE was a predictive factor for the tumor response

According to Response Evaluation Criteria in Cancer of the Liver (RECICL), the treatment effect (TE) was defined as follows: TE4, tumor necrosis of 100% or 100% reduction; TE3, tumor necrosis of 50%-100% or 50%-100% reduction in tumor size; TE1, tumor enlargement of > 50% regardless of necrosis; TE2, effect other than TE3 or TE1. B-TACE: Balloon-occluded transcatheter arterial chemoembolization; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; RR: Response rate; NA: Not available; C-TACE: Conventional transcatheter arterial chemoembolization; CT: Computed tomography.